PiCRUST prediction of the functional potential of a microbial community based on 16S rRNA gene sequencing data. by Jun Ho Song (1675123)

A 60-year-old male with a hyperacute cardioembolic infarction fifteen hours after the onset. by Daichi Momosaka (6160418)

“…<b>G:</b> MTR_asym spectra show decreased MTR_asym (3.5ppm) or APTW signal (%) in the infarct area compared to the CNAWM. mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; FLAIR, fluid attenuated inversion recovery; DWI, diffusion-weighted imaging; ROI, region-of-interest; ADC, apparent diffusion coefficient; APTW, amide proton transfer-weighted; CEST, chemical exchange saturation transfer; CNAWM, contralateral normal-appearing white matter; S_sat(ppm) and S0, the signal intensities obtained with and without selective radiofrequency saturation pulse irradiation, respectively; APT₁₀, APT₂₅, APT₅₀, APT₇₅, and APT₉₀ correspond to the 10th, 25th, 50th, 75th, and 90th percentiles of the APTW signal value within the ROI, respectively.…”

A 59-year-old male with a subacute atherosclerotic infarction nine days after the onset. by Daichi Momosaka (6160418)

“…<b>G:</b> MTR_asym spectra show decreased MTR_asym(3.5ppm) or APTW signal (%) in the infarct area compared to the CNAWM. mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; FLAIR, fluid attenuated inversion recovery; DWI, diffusion-weighted imaging; ROI, region-of-interest; ADC, apparent diffusion coefficient; APTW, amide proton transfer-weighted; CEST, chemical exchange saturation transfer; CNAWM, contralateral normal-appearing white matter; S_sat (ppm) and S₀, the signal intensities obtained with and without selective radiofrequency saturation pulse irradiation, respectively; APT₁₀, APT₂₅, APT₅₀, APT₇₅, and APT₉₀, correspond to the 10th, 25th, 50th, 75th, and 90th percentiles of APTW signal value, respectively.…”

16 Weeks of Progressive Barefoot Running Training Changes Impact Force and Muscle Activation in Habitual Shod Runners by Ana Paula da Silva Azevedo (3373688)

“…The magnitude of first peak of VGRF (Fy1) and the impulse of the first 50 ms decreased after training for BF and SH (p<0.01). …”

Pulse Ultrasound-Based Response Enhancement of a MOX Gas Sensor by Yumin Yang (5737235)

“…For 2 ppm methanol, the RE by the pulse ultrasound is 50%, relative to the continuous ultrasound, when the pulse width, duty ratio, and working frequency are 0.4 ms, 50%, and 110.1 kHz, respectively. …”

Pulse Ultrasound-Based Response Enhancement of a MOX Gas Sensor by Yumin Yang (5737235)

“…For 2 ppm methanol, the RE by the pulse ultrasound is 50%, relative to the continuous ultrasound, when the pulse width, duty ratio, and working frequency are 0.4 ms, 50%, and 110.1 kHz, respectively. …”

Initial treatment regimen. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

Patients baseline characteristics. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

Overall survival. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

Progression-free survival by treatment. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

Maintenance regimen and adverse event management. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

BCC-specific survival. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

Opioid consumption data. by Wali U. Pirzada (22278071)

“…Orthopaedic Surgery patients saw a mean 45% reduction in prescription size from 462 MMEs (range: 50–7200 MMEs) to 197 MMEs (range: 25–2400 MMEs) (p < .001), while General Surgery patients experienced a mean 38% reduction from 100 MMEs (range: 25–150 MMEs) to 60 MMEs (range: 25–150 MMEs) (p < .001). …”

Prescription data. by Wali U. Pirzada (22278071)

“…Orthopaedic Surgery patients saw a mean 45% reduction in prescription size from 462 MMEs (range: 50–7200 MMEs) to 197 MMEs (range: 25–2400 MMEs) (p < .001), while General Surgery patients experienced a mean 38% reduction from 100 MMEs (range: 25–150 MMEs) to 60 MMEs (range: 25–150 MMEs) (p < .001). …”

Refill rate by surgical specialty. by Wali U. Pirzada (22278071)

“…Orthopaedic Surgery patients saw a mean 45% reduction in prescription size from 462 MMEs (range: 50–7200 MMEs) to 197 MMEs (range: 25–2400 MMEs) (p < .001), while General Surgery patients experienced a mean 38% reduction from 100 MMEs (range: 25–150 MMEs) to 60 MMEs (range: 25–150 MMEs) (p < .001). …”

Noncontinuous data on opioid use. by Wali U. Pirzada (22278071)

“…Orthopaedic Surgery patients saw a mean 45% reduction in prescription size from 462 MMEs (range: 50–7200 MMEs) to 197 MMEs (range: 25–2400 MMEs) (p < .001), while General Surgery patients experienced a mean 38% reduction from 100 MMEs (range: 25–150 MMEs) to 60 MMEs (range: 25–150 MMEs) (p < .001). …”

Effect of AGPAT3 downregulation on the mTORC1 signaling pathway. by Hadi Alizadeh (20854757)

Subjects:

Introduction of potential genes and signal pathways related to cisplatin resistance in the A2780 cell line based on Bioinformatics analysis. by Hadi Alizadeh (20854757)

Subjects:

Mechanism of AGPAT3-mediated mTORC1 activation and its downstream effects. by Hadi Alizadeh (20854757)

Subjects:

Effect of AGPAT3 overexpression on mTORC1 signaling pathway. by Hadi Alizadeh (20854757)

Subjects: